Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) General Counsel Junlin Ho sold 4,695 shares of Scholar Rock stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $8.98, for a total value of $42,161.10. Following the completion of the sale, the general counsel now directly owns 204,076 shares in the company, valued at $1,832,602.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Scholar Rock Price Performance
Shares of NASDAQ SRRK opened at $8.49 on Thursday. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.58 and a quick ratio of 6.58. Scholar Rock Holding Co. has a 52-week low of $5.93 and a 52-week high of $21.17. The business has a 50-day moving average price of $12.24 and a 200 day moving average price of $14.85.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last announced its earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). During the same quarter in the previous year, the business earned ($0.46) earnings per share. Equities analysts predict that Scholar Rock Holding Co. will post -2.4 EPS for the current year.
Institutional Trading of Scholar Rock
Analyst Ratings Changes
A number of research firms have weighed in on SRRK. Piper Sandler reissued an “overweight” rating and set a $28.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 26th. Raymond James started coverage on Scholar Rock in a research note on Thursday, March 28th. They set a “strong-buy” rating and a $30.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Scholar Rock in a research report on Tuesday, May 7th. BMO Capital Markets lifted their target price on Scholar Rock from $29.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, June 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Scholar Rock in a report on Tuesday, June 4th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Scholar Rock currently has a consensus rating of “Buy” and a consensus target price of $26.00.
Read Our Latest Analysis on SRRK
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Read More
- Five stocks we like better than Scholar Rock
- Most Volatile Stocks, What Investors Need to Know
- Signet Jewelers Stock Poised for Rebound After Earnings Drop
- Market Cap Calculator: How to Calculate Market Cap
- Airship AI Lands New Contract: Stock Soars 16% and More to Come
- What is a Death Cross in Stocks?
- Restoration Hardware Stock: Should You Buy After Earnings Drop?
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.